NYSEARCA:XPH SPDR S&P Pharmaceuticals ETF (XPH) Price, Holdings, & News $43.42 +0.17 (+0.39%) (As of 12/20/2024 05:23 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisChartDividendHeadlinesHoldingsOwnershipRatings About SPDR S&P Pharmaceuticals ETF (NYSEARCA:XPH) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get XPH alerts:Sign Up Key Stats Today's Range$43.07▼$43.9750-Day Range$43.25▼$48.2952-Week Range$38.88▼$48.76Volume58,355 shsAverage Volume43,590 shsMarket Capitalization$210.59 millionAssets Under Management$156.53 millionDividend Yield1.54%Net Expense Ratio0.35%Aggregate RatingModerate Buy ETF OverviewSPDR S&P Pharmaceuticals ETF (the Fund) seeks to replicate as closely as possible the total return performance of the S&P Pharmaceuticals Select Industry Index. The S&P Pharmaceuticals Select Industry Index represents the pharmaceuticals sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Fund invests substantially all, but at least 80%, of its total assets in the securities comprising the Index. In addition, the Fund may invest in equity securities that are not included in the Index, cash and cash equivalents or money market instruments, such as repurchase agreements and money market funds. The Pharmaceuticals Index is a modified equal weight index. SSgA Funds Management, Inc. is the Fund's investment advisor.Read More… SPDR S&P Pharmaceuticals ETF ExpensesTypeXPHHealth Care ETFsEquity ETFsNYSEARCA ETFsAll ETFsManagement Fee0.35%0.57%0.55%0.51%0.52%Other Expenses0.00%0.30%0.49%0.57%0.53%Total Expense0.35%0.70%0.71%0.73%0.71%Fee Waiver0.00%-0.45%-0.51%-0.67%-0.56%Net Expense0.35%0.61%0.61%0.58%0.59% Receive XPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for SPDR S&P Pharmaceuticals ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address XPH ETF News HeadlinesSPDR® S&P Regional Banking ETFDecember 20 at 8:13 AM | morningstar.com1 No-Brainer Small-Cap S&P Index Fund to Buy Right Now for Less Than $200November 21, 2024 | msn.comHow Low-Cost Stocks Generate Monthly IncomeAre you ready to transform your investment strategy and generate a steady monthly income? We’re excited to offer you our exclusive report, "Options Trading Strategy: 2 (Surprisingly) Low-Cost Stocks Primed for Generating Monthly Income," FREE!December 21, 2024 | Darwin (Ad)Shuttle Pharmaceuticals prices $4.5M at-the-market offering at $1.525 per shareOctober 30, 2024 | markets.businessinsider.comBalanced Outlook on Apellis Pharmaceuticals: Promising Empaveli Data Amid Syfovre Growth ChallengesOctober 28, 2024 | markets.businessinsider.comBristol Myers Squibb: A High-Yield Bargain With Growth On The HorizonOctober 6, 2024 | seekingalpha.comSee More Headlines XPH ETF - Frequently Asked Questions How have XPH shares performed this year? SPDR S&P Pharmaceuticals ETF's stock was trading at $41.62 on January 1st, 2024. Since then, XPH shares have increased by 4.3% and is now trading at $43.42. View the best growth stocks for 2024 here. Who are SPDR S&P Pharmaceuticals ETF's major shareholders? SPDR S&P Pharmaceuticals ETF's top institutional investors include Clal Insurance Enterprises Holdings Ltd (16.49%), BNP Paribas Financial Markets (3.08%), First Citizens Bank & Trust Co. (1.49%) and MAI Capital Management (0.79%). How do I buy shares of SPDR S&P Pharmaceuticals ETF? Shares of XPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of SPDR S&P Pharmaceuticals ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that SPDR S&P Pharmaceuticals ETF investors own include NVIDIA (NVDA), Pfizer (PFE), Adobe (ADBE), Applied Materials (AMAT), Chevron (CVX), JPMorgan Chase & Co. (JPM) and Meta Platforms (META). Fund Details IssuerSSgA Fund NameSPDR S&P Pharmaceuticals ETF Tax ClassificationRegulated Investment Company Stock ExchangeNYSEARCACurrent SymbolNYSEARCA:XPH Inception Date6/19/2006 Fund ManagerMichael Feehily, Karl Schneider, Keith Richardson Webwww.spdrs.com Phone+1-617-6644738Fund Focus Asset ClassEquity BenchmarkS&P Pharmaceuticals Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionNorth America Number of Holdings48 Fund Statistics Assets Under Management$156.53 million Average Daily Volume$49,817.20 Discount/Premium-0.06% Administrator, Advisor and Custodian AdministratorSSgA Funds Management, Inc. AdvisorSSgA Funds Management, Inc. CustodianState Street Bank and Trust Company DistributorState Street Global Advisors Funds Distributors, LLC Transfer AgentState Street Bank and Trust Company TrusteeN/A Lead Market MakerCitadel Options OptionableOptionable Options Volume2 Put Options1 Call Options1 Short Interest667,800 shs Miscellaneous Outstanding Shares4,850,000Beta0.87 Creation Unit50,000 Creation Fee$250.00 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Top 10 XPH HoldingsCorcept Therapeutics (NASDAQ:CORT)Holding Weight: 5.37%Longboard Pharmaceuticals (NASDAQ:LBPH)Holding Weight: 4.19%Bristol-Myers Squibb (NYSE:BMY)Holding Weight: 4.18%Intra-Cellular Therapies (NASDAQ:ITCI)Holding Weight: 4.01%Jazz Pharmaceuticals (NASDAQ:JAZZ)Holding Weight: 3.95%Viatris (NASDAQ:VTRS)Holding Weight: 3.92%Axsome Therapeutics (NASDAQ:AXSM)Holding Weight: 3.62%Perrigo (NYSE:PRGO)Holding Weight: 3.57%Catalent (NYSE:CTLT)Holding Weight: 3.56%Edgewise Therapeutics (NASDAQ:EWTX)Holding Weight: 3.39%Full Holdings DetailsXPH Sector ExposureXPH Industry Exposure This page (NYSEARCA:XPH) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SPDR S&P Pharmaceuticals ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share SPDR S&P Pharmaceuticals ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.